Historically, the stock has demonstrated a strong likelihood of positive returns following its earnings announcements.

The health sector sees dynamic shifts with Thailand's poultry industry set for growth, breakthrough breast cancer treatments ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

To sustain momentum, Hims recently announced a deal with Novo Nordisk A/S (NYSE: NVO) to distribute branded Wegovy at ...

Hims & Hers Health Inc. is cutting more than 4% of its workforce as it pivots away from selling cheap copycat versions of ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...

The short-sale attack on Tempus AI (TEM) heated up on Wednesday. The stock’s rally halted after it lost 19.23% to close at ...

Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a ...

We recently published a list of 10 Stocks Got Wiped Out. Are You Holding Any? In this article, we are going to take a look at ...